NCT03818828已完成2 期
A Multicenter, Open Label Phase 2 Pilot Trial of Subjects With Non-Healing Venous Leg Ulcers Treated With Standard Care Plus Cryopreserved Human Umbilical Cord (TTAX01)
Tissue Tech Inc.11 个研究点 分布在 1 个国家目标入组 31 人开始时间: 2019年2月14日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 31
- 试验地点
- 11
- 主要终点
- Complete wound healing
研究概览
简要总结
It is hypothesized that application at 4-week intervals of the human umbilical cord tissue TTAX01 to the surface of a well debrided, nonhealing venous leg ulcer (VLU) will result in a high proportion of wounds showing complete healing within 12 weeks of initiating therapy. This open label pilot study provides a framework for a larger, controlled study. The purposes for conducting this study are to evaluate the functionality of the protocol and to obtain an estimate of product safety and efficacy when applied according to the protocol instructions, and measured according to the stated endpoints.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Provide informed consent.
- •Age ≥ 18 years and of either sex.
- •Willing to comply with protocol instructions, including allowing all study assessments.
- •Have a venous leg ulcer (VLU) between the knee and ankle (at or above the malleolus), with a surface area in the range of ≥ 2.0 cm2 and ≤ 18.0 cm2 confirmed using the wound imaging and measurement device.
- •Venous insufficiency confirmed by duplex Doppler ultrasound examination for valvular or venous incompetence.
- •Arterial supply adequacy confirmed by any one of the following: Great toe pressure ≥ 50 mm/Hg; Systolic blood pressure Ankle Brachial Index (ABI) in the range ≥ to 0.8 to ≤ 1.1; TcPO2 ≥ to 40 mmHg from the foot
- •Target ulcer involves a full thickness skin loss, but WITHOUT exposure of tendon, muscle, or bone
- •Target ulcer duration ≥ 6 weeks but ≤ 104 weeks
- •For diabetic subjects an HbA1C < 12.0% per the local lab report
排除标准
- •Therapy with another investigational agent within thirty (30) days of Screening, or during the study.
- •A target ulcer of non-venous etiologies (e.g., sickle cell anemia, necrobiosis lipoidica diabeticorum, pyoderma gangrenosum, vasculopathic or vasculitic).
- •Deep Vein Thrombosis (DVT) that is acute, defined as the first 10 days from onset of symptoms, or any DVT for which compression bandaging is considered by the Investigator to be contraindicated.
- •Clinical evidence of ulcer bed infection as described in the Study Guide.
- •Documented history of osteomyelitis at the target wound location within 6 months preceding the Screening Visit.
- •Refusal of or inability to tolerate compression therapy.
- •The subject is pregnant
- •The subject is a nursing mother
- •The subject is a woman of child-bearing potential who is unwilling to avoid pregnancy or use an appropriate form of birth control (adequate birth control methods are defined as: topical, oral, implantable, or injectable contraceptives; spermicide in conjunction with a barrier such as a condom or diaphragm; IUD; or surgical sterilization of partner).
- •Therapy of the target ulcer with other birth tissue products, autologous skin graft, Apligraf®, or Dermagraft® within 30 days preceding the Screening Visit.
- •Therapy of the target ulcer with topical growth factors within 1 week preceding the Screening Visit.
- •Current therapy with systemic antibiotics.
- •Current systemic therapy with cytotoxic drugs.
- •Current therapy with chronic (> 10 days) oral corticosteroids.
- •Current therapy with TNF alpha inhibitors other than Trental® (pentoxifylline).
- •History of cancer in the preceding 5 years (other than carcinoma in situ of the cervix or adequately treated non-melanoma skin cancers).
- •The subject has had previous use of NEOX® CORD 1K®, CLARIX® CORD 1K®, or TTAX01 applied to the index ulcer
- •The subject has an allergy to Amphotericin B or glycerol
- •The subject has an allergy to primary or secondary dressing materials used in this trial
- •Per Investigator's discretion the subject is not appropriate for inclusion in the trial, e.g., undergoing surgical treatments or the subject currently has sepsis, i.e., life-threatening organ dysfunction caused by a dysregulated host response to infection
结局指标
主要结局
Complete wound healing
时间窗: 12-weeks
Proportion of subjects who achieve complete wound closure over the 12-week treatment period from baseline with a 4 week followup to confirm wound healing.
次要结局
- Time to complete wound healing(up to 12 weeks)
- Complete wound healing(up to 12 weeks)
- Changes in pain using the numeric rating scale(up to 12 weeks)
研究者
研究点 (11)
Loading locations...
相似试验
已完成
2 期
Phase 2 Pilot Trial of Subjects With Complex Non-healing Diabetic Foot Ulcers Treated With Standard Care Plus Cryopreserved Umbilical Cord Allograft (TTAX01)Non-healing WoundNon-healing Diabetic Foot UlcerDiabetic Foot InfectionNCT03230175Tissue Tech Inc.32
已完成
2 期
hCT-MSC in Children With Autism Spectrum DisorderAutism Spectrum DisorderAutismNCT04089579Joanne Kurtzberg, MD137
终止
2 期
TTAC-0001 Phase II Trial With Recurrent Glioblastoma Progressed on BevacizumabRecurrent GlioblastomaNCT03856099PharmAbcine19
已完成
2 期
Efficacy and Safety of Tisagenlecleucel in Adult Patients With Refractory or Relapsed Follicular LymphomaFollicular LymphomaNCT03568461Novartis Pharmaceuticals98
终止
1 期
Phase I/II Clinical Study of 1A46 Drug SubstanceAdvanced MalignanciesNCT05987605BioRay Pharmaceutical Co., Ltd.4